-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical has been recognized as a leading enterprise for its contributions to high-quality development in China’s pharmaceutical industry—Headquarters Power.
Category:
Time：2022-05-04
On April 28, the "33rd National Pharmaceutical Economic Information Conference and 2021 Pharmaceutical Economic Person of the Year Award Ceremony," guided by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and organized by Pharmaceutical Economic News, was held online in a grand manner. After rigorous screening, Shijiazhuang No.4 Pharmaceutical was recognized as a leading player in the industry—a Chinese enterprise that has achieved high-quality development in the pharmaceutical sector (2021 Strong Company).
On April 28, the "33rd National Pharmaceutical Economic Information Conference and 2021 Pharmaceutical Economic Person of the Year Award Ceremony," guided by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and organized by Pharmaceutical Economic News, was held online with great solemnity. After rigorous screening, Shijiazhuang Fourth Pharmaceutical was recognized as a leading player in the industry—a Chinese enterprise that has achieved high-quality development in the pharmaceutical sector (2021 Strong Company).
In 2021, as the country’s 14th Five-Year Plan got underway, the pharmaceutical industry entered a new stage of high-quality development. Healthcare reform has now reached deeper waters, and industrial policies such as drug review reforms and volume-based procurement are compelling the industry to further upgrade its innovation capabilities. Meanwhile, the momentum of the digital wave is reshaping the industry’s new ecosystem—including drug R&D, supply chain management, prescription circulation, and online healthcare. Upholding integrity while fostering innovation has become the only viable path for China to advance toward becoming a global pharmaceutical powerhouse in this new stage. Under the national strategy of “innovation-driven development,” innovative elements in the pharmaceutical sector continue to converge, and innovation capacity keeps rising. A number of outstanding enterprises in the industry are emerging as pioneers, practitioners, and leaders in China’s pharmaceutical sector. Shijiazhuang Fourth Pharmaceutical stands out as a prominent example, continuously driving its enterprise toward the high end of the industry through innovation, and has become a key force behind the rise of leading companies in the sector.
It is reported that in 2021, the "Pharmaceutical Economic Daily" selected the "Leading Forces—China's Pharmaceutical Industry High-Quality Development Achievements Enterprises (2021)" based on the keyword "Leading Forces," using dimensions such as "international recognition, stable operational index, performance indicators, and social responsibility index." This selection aimed to recognize industry leaders who remain true to their original aspirations and continue forging ahead.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license